AU7700400A - Uroguanylin as an intestinal cancer inhibiting agent - Google Patents

Uroguanylin as an intestinal cancer inhibiting agent

Info

Publication number
AU7700400A
AU7700400A AU77004/00A AU7700400A AU7700400A AU 7700400 A AU7700400 A AU 7700400A AU 77004/00 A AU77004/00 A AU 77004/00A AU 7700400 A AU7700400 A AU 7700400A AU 7700400 A AU7700400 A AU 7700400A
Authority
AU
Australia
Prior art keywords
uroguanylin
inhibiting agent
intestinal cancer
cancer inhibiting
intestinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU77004/00A
Inventor
Mark G Currie
Kunwar Shailubhai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Publication of AU7700400A publication Critical patent/AU7700400A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU77004/00A 1999-10-06 2000-10-04 Uroguanylin as an intestinal cancer inhibiting agent Abandoned AU7700400A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15795099P 1999-10-06 1999-10-06
US60157950 1999-10-06
PCT/US2000/021998 WO2001025266A1 (en) 1999-10-06 2000-10-04 Uroguanylin as an intestinal cancer inhibiting agent

Publications (1)

Publication Number Publication Date
AU7700400A true AU7700400A (en) 2001-05-10

Family

ID=22566032

Family Applications (1)

Application Number Title Priority Date Filing Date
AU77004/00A Abandoned AU7700400A (en) 1999-10-06 2000-10-04 Uroguanylin as an intestinal cancer inhibiting agent

Country Status (4)

Country Link
EP (1) EP1220872A1 (en)
JP (1) JP2003516316A (en)
AU (1) AU7700400A (en)
WO (1) WO2001025266A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002078683A1 (en) 2001-03-29 2002-10-10 Synergy Pharmaceuticals, Inc. Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
CN101787073B (en) 2003-01-28 2013-12-25 艾恩伍德医药品股份有限公司 Methods and compositions for treatment of gastrointestinal disorders
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1599165A4 (en) 2003-02-10 2010-09-08 Univ Jefferson The use of gcc ligands
US20070010450A1 (en) 2003-06-13 2007-01-11 Microbia, Inc., A Massachusetts Corporation Methods and compositions for the treatment of gastrointestinal disorders
US7494979B2 (en) 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA3089569C (en) 2007-06-04 2023-12-05 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
WO2009033780A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of growth hormone-releasing factor and/or k237 as a therapeutic agents
EP2296685B1 (en) 2008-06-04 2015-09-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CA2994066A1 (en) 2008-12-03 2010-06-10 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
SI2603232T1 (en) 2010-08-11 2020-03-31 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2621509A4 (en) 2010-09-15 2016-08-03 Synergy Pharmaceuticals Inc Formulations of guanylate cyclase c agonists and methods of use
WO2013016662A1 (en) * 2011-07-28 2013-01-31 Memorial Sloan-Kettering Cancer Center Diagnosis and treatment of parkinson's disease
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP2016514670A (en) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase receptor agonists in combination with other drugs
CA3169588A1 (en) * 2020-01-31 2021-08-05 Sequela, Inc. Biomarker, methods, and compositions thereof for evaluation or management of kidney function or diagnosing or aid in diagnosing kidney dysfunction or kidney disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5879656A (en) * 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
US5962220A (en) * 1993-10-26 1999-10-05 Thomas Jefferson University Compositions that specifically bind to colorectal cells and methods of using the same
ATE245163T1 (en) * 1996-05-03 2003-08-15 Univ Jefferson VACCINE AGAINST METASTASIC COLORECTAL CANCER.
WO1999039748A1 (en) * 1998-02-06 1999-08-12 Nycomed Imaging As Targeting immunoreagents useful in therapeutic and diagnostic compositions and methods

Also Published As

Publication number Publication date
WO2001025266A1 (en) 2001-04-12
JP2003516316A (en) 2003-05-13
EP1220872A1 (en) 2002-07-10

Similar Documents

Publication Publication Date Title
AU2020501A (en) Chemotherapy treatment
AU7700400A (en) Uroguanylin as an intestinal cancer inhibiting agent
AU6908500A (en) Treatment for narcolepsy
AU5259100A (en) Medicament
AU1173201A (en) Skin-gripper
AU3092999A (en) Digital-timeshare-exchange
AU6599800A (en) Endoscope
AU5967600A (en) Candystraw
AU4115400A (en) Short-circuiter
AU2578200A (en) Jammer
AU1554301A (en) Radioprotecting agent
AU6440900A (en) Homogentisate-dioxygenase
AU7730100A (en) Endoscope system
AU3191100A (en) Ligand-bonded complex
AU4561600A (en) Benzofuranylaminoalcohols
AU5833100A (en) Survival jacket
AU1901801A (en) Glucofuranoses
AU2582200A (en) Windturbine
AU7513400A (en) Hydantoin-racemase
AU1915601A (en) Periotome
AU7919100A (en) Clear hair-treatment agent
AUPQ421699A0 (en) Tumour suppressor factor
AU6017900A (en) Novel tumor suppressor gene
AU3610300A (en) Single-stage-to-orbit rocket
AU5416100A (en) Retinoscopes

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase